Jamey M.  Mock net worth and biography

Jamey Mock Biography and Net Worth

CFO of Moderna

As Chief Financial Officer, Jamey Mock oversees financial, business development and business services functions at Moderna. Mr. Mock previously served as Senior Vice President and CFO of PerkinElmer, Inc., a life sciences, diagnostics and analytical solutions company, since May 2018. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. During that time, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for growth and profitability. Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company, both in the United States and overseas. Mr. Mock holds a Bachelor of Arts in economics from St. Lawrence University.

What is Jamey M. Mock's net worth?

The estimated net worth of Jamey M. Mock is at least $880,566.66 as of July 8th, 2024. Mr. Mock owns 7,269 shares of Moderna stock worth more than $880,567 as of July 22nd. This net worth evaluation does not reflect any other assets that Mr. Mock may own. Learn More about Jamey M. Mock's net worth.

How do I contact Jamey M. Mock?

The corporate mailing address for Mr. Mock and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Jamey M. Mock's contact information.

Has Jamey M. Mock been buying or selling shares of Moderna?

Over the course of the past ninety days, Jamey M. Mock has sold $81,467.36 in shares of Moderna stock. Most recently, James M. Mock sold 689 shares of the business's stock in a transaction on Monday, July 8th. The shares were sold at an average price of $118.24, for a transaction totalling $81,467.36. Following the completion of the sale, the chief financial officer now directly owns 7,269 shares of the company's stock, valued at $859,486.56. Learn More on Jamey M. Mock's trading history.

Who are Moderna's active insiders?

Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.

Are insiders buying or selling shares of Moderna?

During the last year, insiders at the sold shares 57 times. They sold a total of 823,004 shares worth more than $99,620,994.77. The most recent insider tranaction occured on July, 17th when Director Noubar Afeyan sold 15,000 shares worth more than $1,842,600.00. Insiders at Moderna own 15.7% of the company. Learn More about insider trades at Moderna.

Information on this page was last updated on 7/17/2024.

Jamey M. Mock Insider Trading History at Moderna

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/8/2024Sell689$118.24$81,467.367,269View SEC Filing Icon  
5/28/2024Sell648$162.47$105,280.565,726View SEC Filing Icon  
4/8/2024Sell705$101.93$71,860.655,048View SEC Filing Icon  
2/29/2024Sell647$94.57$61,186.794,300View SEC Filing Icon  
1/8/2024Sell772$109.75$84,727.003,632View SEC Filing Icon  
10/6/2023Sell2,858$102.50$292,945.002,952View SEC Filing Icon  
See Full Table

Jamey M. Mock Buying and Selling Activity at Moderna

This chart shows James M Mock's buying and selling at Moderna by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Moderna Company Overview

Moderna logo
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $122.50
Low: $120.44
High: $124.06

50 Day Range

MA: $135.45
Low: $115.95
High: $166.61

2 Week Range

Now: $122.50
Low: $62.55
High: $170.47

Volume

1,787,408 shs

Average Volume

4,062,705 shs

Market Capitalization

$46.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66